Thrombin Potentiation of Factor VIII Procoagulant Activity: Assessment by the Two-Stage Assay

Robert G Kopitsky; Mary Ellen P Switzer; Patrick A McKee

doi:10.1055/s-0038-1657150

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1982; 47(02): 145-149
DOI: 10.1055/s-0038-1657150

Original Article

Schattauer GmbH Stuttgart

Thrombin Potentiation of Factor VIII Procoagulant Activity: Assessment by the Two-Stage Assay

Authors

Robert G Kopitsky

The Howard Hughes Medical Institute Laboratories, Department of Medicine and the Department of Biochemistry Duke University Medical Center, Durham NC, U.S.A.
Mary Ellen P Switzer

The Howard Hughes Medical Institute Laboratories, Department of Medicine and the Department of Biochemistry Duke University Medical Center, Durham NC, U.S.A.
Patrick A McKee

The Howard Hughes Medical Institute Laboratories, Department of Medicine and the Department of Biochemistry Duke University Medical Center, Durham NC, U.S.A.

Abstract

PDF Download

Summary

Factor VIII (FVIII) procoagulant activity is the function of a plasma glycoprotein that is missing or inactive in patients with classic hemophilia. Numerous studies have shown that trace thrombin causes rapid enhancement followed by gradual inactivation of FVIII procoagulant activity. Recent evidence suggests that thrombin activation of the FVIII/von Willebrand factor (vWF) protein is required for inactivation to occur. All of these studies have used the one-stage partial thromboplastin time to assay FVIII activity. Other investigators have used the two-stage assay of FVIII activity and have been unable to demonstrate thrombin-induced enhancement of FVIII activity, although inactivation has consistently occurred. We performed experiments designed to help resolve this disagreement, using the two-stage assay specifically modified to detect thrombin potentiation of FVIII activity. The length of the first-stage incubation time was found to be critical in demonstrating the initial effect of thrombin on FVIII activity. Taking advantage of this finding we were able to show a 4.1 ± 0.5-fold enhancement of FVIII activity upon incubating purified FVin/vWF with 0.04 NIH unit thrombin per ml. The apparent enhancement of FVEQ activity declined with increasing thrombin concentration. Incubation with 0.08, 0.16, and 0.32 NIH unit thrombin per ml resulted in only 3.2 ± 0.5, 2.6 ± 0.5 and 1.5 ± 0.3-fold enhancement, respectively, of FVIII activity. As with results from the one-stage assay, activation was followed by slow inactivation of FVIH/vWF. Using the two-stage assay we also showed 100% inactivation and 100% inhibition of FVIII activity by plasmin and human anti-FVUI IgG, respectively. Plasmin inactivation of FVIII activity showed a dose-response effect. Thrombin was unable to activate plasmin-degraded FVin/vWF. Our results show that thrombin potentiation of FVni activity is easily demonstrable in the two-stage assay. These findings support the contention that activation of FVm activity by thrombin is prerequisite for inactivation and underscore the importance of thrombin activation of FVHI/vWF in the intrinsic clotting system.

Key words

FVIII/vWF-factor VIII/von Willebrand factor - Thrombin and factor VIII - Activated factor VIII - Two-stage factor VIII assay

PDF (1253 kb)

References

References
1 Rapaport SI, Schiffman S, Patch MJ, Ames SB. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity. Blood 1963; 21: 221-235
2 Legaz ME, Schmer G, Counts RB, Davie EW. Isolation and characterization of human factor VIII (antihemophilic factor). J Biol Chem 1973; 248: 3946-3955
3 McKee PA, Andersen JC, Switzer ME. Molecular structural studies of human factor VIII. Ann NY Acad Sci 1975; 240: 8-33
4 Hoyer LW, Trabold NC. The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation. J Lab Clin Med 1981; 97: 50-64
5 Hultin MB, Nemerson Y. Activation of factor X by factors IX_a and VIII; A specific assay for factor IX_a in the presence of thrombin-activated factor VIII. Blood 1978; 52: 928-940
6 van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIII_a in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442
7 Switzer MEP, Pizzo SV, McKee PA. Is there a precursive, relatively procoagulant-inactive form of normal antihemophilic factor (factor-VIII)?. Blood 1979; 54: 916-927
8 Switzer MEP, McKee PA. Reactions of thrombin with human factor VIII/von Willebrand factor protein. J Biol Chem 1980; 255: 10606-10611
9 Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 1980; 19: 401-410
10 Macfarlane RG, Biggs R, Ash BJ, Denson KWE. The interaction of factors VIII and IX. Br J Haematol 1964; 10: 530-541
11 Biggs R, Macfarlane RG, Denson KWE, Ash BJ. Thrombin and the interactions of factors VIII and IX. Br J Haematol 1965; 11: 276-295
12 Niemetz J, Nossel HL. Activated coagulation factors: in-vivo and in-vitro studies. Br J Haematol 1969; 16: 337-351
13 Vukovich Th, Koller E, Doleschel W. The influence of thrombin on the clotting activity of factor VIII. A study with insolubilized thrombin. Thromb Haemostas 1978; 39: 600-606
14 Cockbum CG, de Beaufre-Apps RJ, Wilson J, Hardisty RM. Parallel destruction of factor VIII procoagulant activity and an 85,000 dalton protein in highly purified factor VIII/vWF. Thromb Res 1981; 21: 295-309
15 Tran TH, Bounameaux H, Marbet GA, Duckert F. Dissociation du facteur VIII humain et recombinaison des fragments VIII-C et VIII-AG. Schweiz med Wschr 1979; 109: 1029-1034
16 Newman J, Johnson AJ, Karpatkin MH, Puszkin S. Methods for the production of clinically effective intermediate- and high-purity factor VIII concentrates. Br J Haematol 1971; 21: 1-20
17 Walther PJ, Steinman HM, Hill RL, McKee PA. Activation of human plasminogen by urokinase. J Biol Chem 1974; 249: 1173-1181
18 Lee H, Tucker D, Allain JP. Rapid isolation and purification of antibody to factor VIII by protein A. Thromb Res 1979; 14: 925-930
19 Biggs R. Human Blood Coagulation. Haemostasis and Thrombosis, 2nd ed. Blackwell Scientific Publications; Oxford: 1976: 661-662
20 Switzer MEP, McKee PA. Immunologic studies of native and modified factor VIII/von Willebrand factor. Blood 1979; 54: 310-321
21 Biggs R. Human Blood Coagulation. 684-688 Haemostasis and Thrombosis, 2nd ed. Blackwell Scientific Publications; Oxford: 1976
22 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41: 637-647
23 Biggs R, Eveling J, Richards G. The assay of antihaemophilic-globulin activity. Br J Haematol 1955; 1: 20-34
24 Kirkwood TBL, Barrowcliffe TW. Discrepancy between one-stage and two-stage assay of factor VIII:C. Br J Haematol 1978; 40: 333-338
25 Neal GG, Chavin SI. The role of factors VIII and IX in the activation of bovine blood coagulation factor X. Thromb Res 1979; 16: 473-484
26 Switzer ME, McKee PA. Effects of thrombin on factor V and factor VIII. Chemistry and Biology of Thrombin. 325-343 Lundblad RL, Fenton II JW, Mann KG. Ann Arbor Science Publishers. Inc.; Ann Arbor: 1977